Monarch Partners Asset Management LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 35.8% during the second quarter, Holdings Channel reports. The firm owned 80,703 shares of the medical research company’s stock after selling 45,000 shares during the period. Monarch Partners Asset Management LLC’s holdings in Charles River Laboratories International were worth $8,163,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Cambridge Advisors Inc. acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $202,000. Advisor Partners LLC acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $208,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $217,000. MAI Capital Management acquired a new position in shares of Charles River Laboratories International during the first quarter valued at approximately $224,000. Finally, Massmutual Trust Co. FSB ADV increased its position in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock valued at $246,000 after buying an additional 130 shares during the last quarter. Institutional investors own 95.81% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 97.97 on Friday. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $102.32. The company has a market capitalization of $4.66 billion, a PE ratio of 25.82 and a beta of 1.02. The stock has a 50 day moving average price of $99.80 and a 200 day moving average price of $91.67.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same period in the prior year, the company posted $1.20 EPS. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International declared that its Board of Directors has authorized a share buyback plan on Wednesday, May 10th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

WARNING: “Monarch Partners Asset Management LLC Has $8.16 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/monarch-partners-asset-management-llc-has-8-16-million-position-in-charles-river-laboratories-international-inc-nysecrl/1477911.html.

Several equities analysts have recently commented on CRL shares. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Jefferies Group LLC restated a “buy” rating and issued a $106.00 price objective on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. restated a “neutral” rating and issued a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. BidaskClub downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Barclays PLC restated a “hold” rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $96.94.

In related news, Director George Massaro sold 3,830 shares of the firm’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total value of $386,102.30. Following the transaction, the director now directly owns 18,731 shares of the company’s stock, valued at approximately $1,888,272.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Ross Smith sold 945 shares of the firm’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $95.00, for a total transaction of $89,775.00. Following the completion of the transaction, the insider now directly owns 14,203 shares in the company, valued at $1,349,285. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,369 shares of company stock worth $7,846,412. Corporate insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.